Zortix
Sign in
NKTRBULLISHIn depth · 4/5

Exceptional maintenance data strengthens ResPeg profile

The bull case was strengthened by ResPeg's strong maintenance data, showing a high percentage of patients maintained response with a convenient dosing schedule of just four shots a year.

Sign in to read the full idea

The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.

NOT INVESTMENT ADVICE · A SUMMARY OF WHAT WAS SAID ON THE PODCAST · VERIFY AGAINST THE SOURCE
NKTR: Exceptional maintenance data strengthens ResPeg profile · Zortix